



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Phosal 50 PG

Cat. No.:	HY-Y1903
CAS No.:	774594-96-6
Target:	Biochemical Assay Reagents
Pathway:	Others
Storage:	4°C, protect from light

Phosal 50 PG

BIOLOGICAL ACTIVITY

Description	Phosal 50 PG is a cosolvent (standardised phosphatidylcholine concentrate). Phosal 50 PG as a carrier for lipophilic compounds, can improve the absorption, efficacy and therapeutic index of the active ingredient ^[1] .
In Vivo	<p>Phosal 50 PG is usually used as a cosolvent.</p> <p>Navitoclax (HY-10087) (100 mg/kg, once a day for 21 days) is formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG and administered p.o. to mice^[2].</p> <p>A-1331852 (HY-19741) (25 mg/kg, daily for 10 days) is formulated in 2.5% DMSO, 10% ethanol, 27.5% PEG 300, and 60% Phosal 50 PG and administered p.o. to mice^[3].</p> <p>Venetoclax (HY-15531) (100 mg/kg, daily for 10 days) is formulated in 10% ethanol, 30% PEG 400, 60% Phosal 50 PG and administered p.o. to mice^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Nat Metab. 2022 Jul 28.
- Clin Sci. 2021 Aug 13;135(15):1873-1895.
- University of Michigan. 2023 Sep.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Khani S, et al. Improved oral bioavailability of mebudipine upon administration in PhytoSolve and Phosal-based formulation (PBF). AAPS PharmSciTech. 2014 Feb;15(1):96-102.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA